Our Milestones

Our Milestones

Charting A Path Towards Success.

Regulatory Approvals

Revenue (Cr.), FY21

Number of Employees

Number of Products

Triton Laboratories was formed to produce Paracetamol API at our Bonthapally facility in Hyderabad.

1984

1990

Triton opened its second manufacturing facility at Jeedimetla to produce multiple APIs.

Granules India Private Limited was incorporated.

1991

1993

Granules established its first PFI facility at Jeedimetla.

Granules became a listed company, after having initial public offerings at the Bombay and Hyderabad Stock Exchanges.

1995

2003

Granules setsup a new large volume PFI facility in Gagillapur and a wholly owned subsidiary - Granules USA for marketing in the US.

A new Paracetamol plant was built in Bonthapally, Hyderabad.

2005

2008

Granules entered into the Finished Dosage segment.

Granules received US FDA approval for its first Abbreviated New Drug Application (ANDA).

2010

2013

Granules established an API R&D facility in Pragathi Nagar, Hyderabad further to strengthen its vision of being an integrated player.

Granules acquired Auctus Pharma – An API Manufacturing Facility with regulatory approvals

2014

2014

Granules sets up a wholly owned subsidiary in the US; Granules Pharmaceutical to focus on formulation R&D to forward integrate its APIs.

Granules entered the Over-the-Counter business in the US through its own label Granules Consumer Healthcare for OTC products to control the value chain.

2015

2016

Granules laid down the foundation for its Oncology OSD Plant in Visakhapatnam.

To nurture skill development Granules Launched Self Directed Team (SDT) program in Manufacturing Units.

2017

2018

Commenced LEAN SIX-Sigma Program at Granules to inculcate continuous improvement in all areas of business process performance.

Granules entered the front-end business for the sale of Rx Products in the US under the GPI Label.

2019

2020

Granules laid the foundation for the largest single manufacturing site for Multi-Unit Pellet system facility.

Received approvals for 11 ANDAs.

2020

2019

Filed first oncology DMF & 7 other DMFs | 12 ANDAs & 3 MAs.